• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过药物重新定位革新卵巢癌治疗，实现加速且具成本效益的治疗。

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

作者信息

Villegas-Vazquez Edgar Yebran, Marín-Carrasco Francisco Pável, Reyes-Hernández Octavio Daniel, Báez-González Andrea S, Bustamante-Montes Lilia Patricia, Padilla-Benavides Teresita, Quintas-Granados Laura Itzel, Figueroa-González Gabriela

机构信息

Laboratorio de Farmacogenética, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.

Department of Molecular Biology and Biochemistry, Wesleyan University, Middletown, CT, United States.

出版信息

Front Oncol. 2025 Jan 14;14:1514120. doi: 10.3389/fonc.2024.1514120. eCollection 2024.

DOI:10.3389/fonc.2024.1514120
PMID:39876896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11772297/
Abstract

Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough experiments across diverse cancer cell lines, which are validated through preclinical models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.

摘要

药物重新定位，即确定现有药物超出其最初预期医学适应症的新用途的做法，是一种变革性策略，正在彻底改变制药生产力。与传统药物开发方法相比，这种创新方法已被证明非常有效。这对于癌症治疗尤为重要，因为对突破性治疗的需求持续增长。本综述重点关注用于卵巢癌治疗的药物重新定位，展示了基于对多种癌细胞系进行的全面实验的深入探索，并通过临床前模型进行了验证。这些见解不仅揭示了这些药物的疗效，还扩展了与其他药剂的潜在协同作用，有利于为癌症患者开发具有成本效益的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/1c192ab94d89/fonc-14-1514120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/b5a6a3fdf0f9/fonc-14-1514120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/866c99475400/fonc-14-1514120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/0d74b9ea94f8/fonc-14-1514120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/eadbc82d61e2/fonc-14-1514120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/1c192ab94d89/fonc-14-1514120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/b5a6a3fdf0f9/fonc-14-1514120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/866c99475400/fonc-14-1514120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/0d74b9ea94f8/fonc-14-1514120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/eadbc82d61e2/fonc-14-1514120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6b5/11772297/1c192ab94d89/fonc-14-1514120-g005.jpg

相似文献

1
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.通过药物重新定位革新卵巢癌治疗，实现加速且具成本效益的治疗。
Front Oncol. 2025 Jan 14;14:1514120. doi: 10.3389/fonc.2024.1514120. eCollection 2024.
2
Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.利用一种新颖的计算药物重定位方法（DrugPredict），快速鉴定出用于癌症治疗的有效药物候选物。
Oncogene. 2018 Jan 18;37(3):403-414. doi: 10.1038/onc.2017.328. Epub 2017 Oct 2.
3
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.卵巢癌药物重定位的现状和展望。
J Gynecol Oncol. 2019 Jan;30(1):e10. doi: 10.3802/jgo.2019.30.e10. Epub 2018 Oct 10.
4
Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery.药物再利用：药物再利用、再循环和发现的新兴工具。
Curr Drug Res Rev. 2021;13(2):101-119. doi: 10.2174/2589977513666210211163711.
5
Drug Repositioning: A Unique Approach to Refurbish Drug Discovery.药物重新定位：一种翻新药物研发的独特方法。
Curr Drug Discov Technol. 2022;19(1):e140122192307. doi: 10.2174/1570163818666210316114331.
6
Drug repositioning for personalized medicine.用于个性化医疗的药物重新定位。
Genome Med. 2012 Mar 30;4(3):27. doi: 10.1186/gm326. eCollection 2012.
7
Does drug repurposing bridge the gaps in management of Parkinson's disease? Unravelling the facts and fallacies.药物重新定位能否填补帕金森病管理中的差距？揭示事实与谬误。
Ageing Res Rev. 2025 Mar;105:102693. doi: 10.1016/j.arr.2025.102693. Epub 2025 Feb 15.
8
Drug Repositioning for Effective Prostate Cancer Treatment.用于有效治疗前列腺癌的药物重新定位。
Front Physiol. 2018 May 15;9:500. doi: 10.3389/fphys.2018.00500. eCollection 2018.
9
Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of breast cancer.罗匹尼罗，一种基于副作用特征用于乳腺癌管理和治疗的系统性重新定位的潜在药物。
Med Hypotheses. 2020 Nov;144:110156. doi: 10.1016/j.mehy.2020.110156. Epub 2020 Aug 2.
10
Innovative approaches in stem cell therapy: revolutionizing cancer treatment and advancing neurobiology - a comprehensive review.干细胞治疗的创新方法：革新癌症治疗与推动神经生物学发展——全面综述
Int J Surg. 2024 Dec 1;110(12):7528-7545. doi: 10.1097/JS9.0000000000002111.

本文引用的文献

1
Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer.协同作用 PD-1/PD-L1 靶向癌症免疫疗法以增强卵巢癌抗肿瘤反应的策略。
Biochem Pharmacol. 2023 Sep;215:115724. doi: 10.1016/j.bcp.2023.115724. Epub 2023 Jul 29.
2
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates.用于靶向卵巢癌中髓源性抑制细胞产生的免疫抑制的药物重新利用：潜在候选药物的文献综述
Pharmaceutics. 2023 Jun 22;15(7):1792. doi: 10.3390/pharmaceutics15071792.
3
Bithionol Restores Sensitivity of Multidrug-Resistant Gram-Negative Bacteria to Colistin with Antimicrobial and Anti-biofilm Effects.
双羟萘酸噻嘧啶恢复多药耐药革兰氏阴性菌对黏菌素的敏感性，具有抗菌和抗生物膜作用。
ACS Infect Dis. 2023 Aug 11;9(8):1634-1646. doi: 10.1021/acsinfecdis.3c00257. Epub 2023 Jul 17.
4
Experimental mouse models for translational human cancer research.用于转化人类癌症研究的实验性小鼠模型。
Front Immunol. 2023 Mar 10;14:1095388. doi: 10.3389/fimmu.2023.1095388. eCollection 2023.
5
Antipsychotic Drug Fluphenazine against Human Cancer Cells.氟奋乃静抗人癌细胞。
Biomolecules. 2022 Sep 23;12(10):1360. doi: 10.3390/biom12101360.
6
Clinical Efficacy Analysis of Biofeedback Electrical Stimulation Combined with Doxycycline in the Treatment of Type IIIA Chronic Prostatitis.生物反馈电刺激联合多西环素治疗ⅢA型慢性前列腺炎的临床疗效分析
Evid Based Complement Alternat Med. 2022 Sep 28;2022:7150204. doi: 10.1155/2022/7150204. eCollection 2022.
7
Harnessing preclinical models for the interrogation of ovarian cancer.利用临床前模型探究卵巢癌。
J Exp Clin Cancer Res. 2022 Sep 16;41(1):277. doi: 10.1186/s13046-022-02486-z.
8
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.ATR 抑制剂在卵巢癌中的作用：探索反应预测生物标志物。
Cells. 2022 Aug 1;11(15):2361. doi: 10.3390/cells11152361.
9
Mechanisms of chemotherapy resistance in ovarian cancer.卵巢癌化疗耐药的机制
Cancer Drug Resist. 2022 Apr 3;5(2):304-316. doi: 10.20517/cdr.2021.147. eCollection 2022.
10
Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study.全球卵巢癌负担、风险因素及时间趋势：一项全球研究。
Cancers (Basel). 2022 Apr 29;14(9):2230. doi: 10.3390/cancers14092230.